REGN רווח למניה בשנים עשר החודשים האחרונים Regeneron Corp

Regeneron Pharmaceuticals (REGN) drives innovation by leveraging academic culture and the expertise of leading geneticists. The annual net income per share demonstrates the fundamental strength of the business, where the value of 45.03 determines the magnitude of the metric. An impeccable medical reputation built on breakthrough drugs is coupled with high liquidity, which effectively mitigates patent risks.
פילוחים אנליטיים ודוחות נתונים של חברת Regeneron Corp (REGN)

This indicator reflects the actual portion of net profit attributable to a single common share per year, allowing for an assessment of capital generation efficiency regardless of the total number of shares issued. By analyzing the rolling earnings per share trend, an investor can determine the monetization pace of the Regeneron Pharmaceuticals (REGN) strategy to protect key drugs and expand into oncology segments through investments in genetics.